Wasserman SM - Search Results

1

Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor.

Kasichayanula S, Grover A, Emery MG, Gibbs MA, Somaratne R, Wasserman SM, Gibbs JP. Kasichayanula S, et al. Among authors: wasserman sm. Clin Pharmacokinet. 2018 Jul;57(7):769-779. doi: 10.1007/s40262-017-0620-7. Clin Pharmacokinet. 2018. PMID: 29353350 Free PMC article. Review.

2

Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data.

Sattar N, Preiss D, Robinson JG, Djedjos CS, Elliott M, Somaratne R, Wasserman SM, Raal FJ. Sattar N, et al. Among authors: wasserman sm. Lancet Diabetes Endocrinol. 2016 May;4(5):403-10. doi: 10.1016/S2213-8587(16)00003-6. Epub 2016 Feb 8. Lancet Diabetes Endocrinol. 2016. PMID: 26868195

3

Evaluation of Evolocumab (AMG 145), a Fully Human Anti-PCSK9 IgG2 Monoclonal Antibody, in Subjects With Hepatic Impairment.

Gibbs JP, Slatter JG, Egbuna O, Geller M, Hamilton L, Dias CS, Xu RY, Johnson J, Wasserman SM, Emery MG. Gibbs JP, et al. Among authors: wasserman sm. J Clin Pharmacol. 2017 Apr;57(4):513-523. doi: 10.1002/jcph.832. Epub 2016 Oct 26. J Clin Pharmacol. 2017. PMID: 27667740 Free PMC article.

4

Impact of Target-Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9).

Gibbs JP, Doshi S, Kuchimanchi M, Grover A, Emery MG, Dodds MG, Gibbs MA, Somaratne R, Wasserman SM, Blom D. Gibbs JP, et al. Among authors: wasserman sm. J Clin Pharmacol. 2017 May;57(5):616-626. doi: 10.1002/jcph.840. Epub 2016 Nov 15. J Clin Pharmacol. 2017. PMID: 27861991 Free PMC article. Clinical Trial.

5

Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab.

Desai NR, Giugliano RP, Wasserman SM, Gibbs JP, Liu T, Scott R, Sabatine MS. Desai NR, et al. Among authors: wasserman sm. JAMA Cardiol. 2017 May 1;2(5):556-560. doi: 10.1001/jamacardio.2016.5395. JAMA Cardiol. 2017. PMID: 28122070 Free PMC article.

6

Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics.

Watts GF, Chan DC, Somaratne R, Wasserman SM, Scott R, Marcovina SM, Barrett PHR. Watts GF, et al. Among authors: wasserman sm. Eur Heart J. 2018 Jul 14;39(27):2577-2585. doi: 10.1093/eurheartj/ehy122. Eur Heart J. 2018. PMID: 29566128

7

Population pharmacokinetics and exposure-response modeling and simulation for evolocumab in healthy volunteers and patients with hypercholesterolemia.

Kuchimanchi M, Grover A, Emery MG, Somaratne R, Wasserman SM, Gibbs JP, Doshi S. Kuchimanchi M, et al. Among authors: wasserman sm. J Pharmacokinet Pharmacodyn. 2018 Jun;45(3):505-522. doi: 10.1007/s10928-018-9592-y. Epub 2018 May 7. J Pharmacokinet Pharmacodyn. 2018. PMID: 29736889 Free PMC article.

8

Comparison of LDL-C Reduction Using Different Evolocumab Doses and Intervals: Biological Insights and Treatment Implications.

Wasserman SM, Sabatine MS, Koren MJ, Giugliano RP, Legg JC, Emery MG, Doshi S, Liu T, Somaratne R, Gibbs JP. Wasserman SM, et al. J Cardiovasc Pharmacol Ther. 2018 Sep;23(5):423-432. doi: 10.1177/1074248418774043. Epub 2018 May 16. J Cardiovasc Pharmacol Ther. 2018. PMID: 29768954

9

Influence of Renal Function on Evolocumab Exposure, Pharmacodynamics, and Safety.

Lee E, Gibbs JP, Emery MG, Block G, Wasserman SM, Hamilton L, Kasichayanula S, Hanafin P, Somaratne R, Egbuna O. Lee E, et al. Among authors: wasserman sm. Clin Pharmacol Drug Dev. 2019 Apr;8(3):281-289. doi: 10.1002/cpdd.650. Epub 2019 Jan 24. Clin Pharmacol Drug Dev. 2019. PMID: 30676701 Free PMC article.

10

AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57).

Desai NR, Giugliano RP, Zhou J, Kohli P, Somaratne R, Hoffman E, Liu T, Scott R, Wasserman SM, Sabatine MS. Desai NR, et al. Among authors: wasserman sm. J Am Coll Cardiol. 2014 Feb 11;63(5):430-3. doi: 10.1016/j.jacc.2013.09.048. Epub 2013 Oct 23. J Am Coll Cardiol. 2014. PMID: 24161333 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

108 results

Search Page